Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Pharmacology

Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing

Ali Mohamed Ali, Melissa A. Penny, Thomas A. Smith, Lesley Workman, Philip Sasi, George O. Adjei, Francesca Aweeka, Jean-René Kiechel, Vincent Jullien, Marcus J. Rijken, Rose McGready, Julia Mwesigwa, Kim Kristensen, Kasia Stepniewska, Joel Tarning, Karen I. Barnes, Paolo Denti, for the WWARN Amodiaquine PK Study Group
Ali Mohamed Ali
aSwiss Tropical and Public Health Institute, Basel, Switzerland
bUniversity of Basel, Basel, Switzerland
cIfakara Health Institute, Bagamoyo, Tanzania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa A. Penny
aSwiss Tropical and Public Health Institute, Basel, Switzerland
bUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Thomas A. Smith
aSwiss Tropical and Public Health Institute, Basel, Switzerland
bUniversity of Basel, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lesley Workman
dDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
eWorldWide Antimalarial Resistance Network (WWARN) Clinical Pharmacology and Southern African Regional Hub, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Philip Sasi
fMuhimbili University of Health and Allied Sciences, Dar-es-Salaam, Tanzania
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George O. Adjei
gCentre for Tropical Clinical Pharmacology and Therapeutics, College of Health Sciences, University of Ghana, Korle Bu, Ghana
hOffice of Research, Innovation and Development, University of Ghana, Legon, Ghana
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Francesca Aweeka
iDepartment of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-René Kiechel
jDrugs for Neglected Diseases Initiative, Geneva, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vincent Jullien
kService de Pharmacologie, Hôpital Européen George Pompidou, Université Paris Descartes, Paris, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marcus J. Rijken
lShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rose McGready
lShoklo Malaria Research Unit, Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Mae Sot, Thailand
mCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julia Mwesigwa
nMedical Research Council Unit, Fajara, the Gambia
oFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, Belgium
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kim Kristensen
pDevelopment DMPK-PKPD, Novo Nordisk, Copenhagen, Denmark
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kasia Stepniewska
mCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
qWorldwide Antimalarial Resistance Network, University of Oxford, Oxford, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joel Tarning
mCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
qWorldwide Antimalarial Resistance Network, University of Oxford, Oxford, United Kingdom
rMahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Joel Tarning
Karen I. Barnes
dDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
eWorldWide Antimalarial Resistance Network (WWARN) Clinical Pharmacology and Southern African Regional Hub, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Denti
dDivision of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Paolo Denti
DOI: 10.1128/AAC.02193-17
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • FIG 1
    • Open in new tab
    • Download powerpoint
    FIG 1

    Structure of the PK model of amodiaquine and desethylamodiaquine. Abbreviations: F, oral bioavailability; KTR, first-order transit rate constant; Ka, absorption rate constant; AQ, amodiaquine; DEAQ, desethylamodiaquine; CL, clearance; Vc, central volume of distribution; Q, Q1, and Q2, intercompartmental clearances; Vp, Vp1, and Vp2, peripheral volumes of distribution.

  • FIG 2
    • Open in new tab
    • Download powerpoint
    FIG 2

    Visual predictive check of the final model describing the plasma concentrations of amodiaquine (AQ) and desethylamodiaquine (DEAQ) versus time in uncomplicated malaria patients from Thailand (THA), Kenya (KEN), Uganda (UGA), Burkina Faso (BKF), and Ghana (GHA). Open circles are the observed data points; solid and dashed lines are the 50th, 5th, and 95th percentiles of the observed data; shaded areas are the simulated (n = 1,000) 95% confidence interval for the same percentile. The y axis represents the plasma concentration on the log scale. Censored data points below the lower limit of quantification were imputed as LLOQ/2 and included in the calculation of percentiles for the observed and the simulation data. The VPC for amodiaquine for both Thailand and Kenya was cut at times of 90 and 60 h, respectively, since beyond these times the concentrations from both observed and simulated data were below the LLOQ.

  • FIG 3
    • Open in new tab
    • Download powerpoint
    FIG 3

    Clearance maturation for amodiaquine (red line) and desethylamodiaquine (blue line) expressed as a fraction of adult clearance predicted from the PK model plotted against postnatal age (assuming that birth occurred at term). The dashed lines indicate the section of the maturation curve that falls in the age range below that observed in the study data and are therefore based on an extrapolation.

  • FIG 4
    • Open in new tab
    • Download powerpoint
    FIG 4

    Simulation results of current recommended and optimized dose regimens for amodiaquine. (A and C) Day 7 plasma desethylamodiaquine concentration (A) and maximum concentration of desethylamodiaquine (C) based on the current recommended dose regimen. (B and D) Predicted desethylamodiaquine day 7 concentration for the optimized dose regimen designed to achieve a concentration ≥75% above the threshold value (B) and Cmax of desethylamodiaquine for the optimized dose regimen (D). The black dashed and solid lines in panels A and B are the median and 80% value of median of the simulated day 7 plasma desethylamodiaquine concentration for the typical patient (representing the expected exposure level from the current dosing recommendation), respectively, and the red lines in panels C and D represents the Cmax upper threshold (575 ng/ml). Simulations for each weight are presented as a box plot for the median and 25th and 75th percentiles, with whiskers representing the 5th and 95th percentiles. The boxes in gray indicate that the simulation for that age range is based on an extrapolation, since no PK data for children of that age were available.

Tables

  • Figures
  • Additional Files
  • TABLE 1

    Patient characteristics at baselinea

    CharacteristicValue(s) for the following study(ies):
    Tarning and colleagues (21, 24)Jullien et al. (23)Mwesigwa et al. (25)Stepniewska et al. (22)Adjei et al. (20)Total
    No. of patients26 (+7)b532061101261
    % of male patients (no. of male patients/total no. of patients)0 (0/26)47.2 (25/53)65.0 (13/20)54.1 (33/61)50.5 (51/101)46.7 (122/261)
    Median (range) age (yr)23.0 (16.0–39.0)24.0 (18.0–60.0)9.0 (6.0–13.0)2.5 (1.0–5.0)6.0 (1.0–14.0)7.6 (1.0–60.0)
    % of patients aged (yr) (no. of patients of the indicated age/total no. of patients):
        <20 (0/26)0 (0/53)0 (0/20)32.8 (20/61)12.9 (13/101)12.6 (33/261)
        2 to <50 (0/26)0 (0/53)0 (0/20)65.6 (40/61)21.8 (22/101)23.8 (62/261)
        5 to <120 (0/26)0 (0/53)90.0 (18/20)1.6 (1/61)53.5 (54/101)28.0 (73/261)
        12+100 (26/26)100 (53/53)10.0 (2/20)0 (0/61)11.9 (12/101)34.6 (93/261)
    % of patients receiving the following drug formulation, treatment regimen (no. of patients receiving the formulation, regimen/total no.):
    AQ + AS, FDC0 (0/26)47 (25/53)0 (0/20)47.5 (29/61)0 (0/101)20.7 (54/261)
    AQ + AS, separate tablets0 (0/26)53 (28/53)100 (20/20)52.5 (32/61)85.2 (86/101)63.6 (166/261)
    AQ alone100 (26/26)0 (0/53)0 (0/20)0 (0/61)14.8 (15/101)15.7 (41/261)
    Enrollment demographic, vital, and laboratory parameters
        Median (range) wt (kg)49.0 (37.0–68.0)59.0 (39.0–90.0)24.5 (20.0–42.0)12.5 (7.0–31.0)18.0 (6.5–93.0)21.0 (6.5–93.0)
        Median (range) total dose (mg/kg)30.5 (28.1–63.0)29.5 (18.0–47.1)24.3 (23.9–26.0)33.7 (14.8–65.6)30.0 (30.0–30.0)30.0 (14.8–65.6)
        Geometric mean (range) parasitemia (no. of parasites/μl)1,142 (96–50,453)c11,923 (1,127–109,356)11,122 (240–174,800)23,110 (1,357–467,600)42,689 (630–566,358)17,952 (96–566,358)
        Median (range) hematocrit (%)32.5 (23.0–40.0)32.5 (23.0–40.0)
        Median (range) hemoglobin concn (g/dl)10.3 (6.7–13.2)d13.2 (9.9–17.7)12.2 (9.7–14.1)8.7 (5.9–12.4)11.6 (6.5–15.1)11.2 (5.9–17.7)
    • ↵a Percentages can be more than 100% due to rounding errors. AQ, amodiaquine; AS, artesunate; FDC, fixed-dose combination.

    • ↵b Seven patients were sampled again after delivery, during another episode of malaria.

    • ↵c The data are for patients with vivax malaria.

    • ↵d Derived on the basis of their hematocrit value.

  • TABLE 2

    Descriptions of population pharmacokinetic and noncompartmental studiesa

    CountryStudy description (authors [reference(s)])Treatment (protocol)Study populationFormulationManufacturerNo. of patientsSampling schedule (protocol)Sample collectionSample storage and assayNo. of samples per patientbLLOQ of AQ/DEAQ concn (ng/ml)
    ThailandcEffect of pregnancy on PK and PD of amodiaquine and desethylamodiaquine (Tarning and colleagues [21, 24])AQ (10 mg/kg) daily for 3 days, 200 mg amodiaquine hydrochloride (153 mg amodiaquine base)Pregnant women (ages, 16 to 39 yr) in their 2nd and 3rd trimester (with follow-up after delivery)AQ aloneSanofi-Aventis, France26 (7)d0, 4, 24, 28, 48, 48.5, 49, 50, 51, 52, 54, 56, 58, and 72 h; 4, 5, 7, 14, 21, 28, 35, and 42 daysA sample was drawn from a catheter during the first 3 days and thereafter by venous puncture and placed into lithium heparin tubesSamples were stored at −20°C and analyzed by LC-MS/MS14/22 (14/22)1/2
    KenyacEfficacy of fixed vs nonfixed dose of ASAQ (Jullien et al. [23])Two tablets of AS-AQ at a fixed dose (100/270 mg) or 4 tablets of AS (50 mg) + 4 tablets of AQ (153 mg) daily for 3 days, 353/200 mg amodiaquine hydrochloride (153/270 mg amodiaquine base)Adults (ages, 18 to 60 yr)AS + AQ at a fixed dose and as a loose formulationSanofi-Aventis, France53Before 1st dose, 15 min to 4 h after 1st dose, 15 min to 4 h after 2nd dose, just before 3rd dose, 15 min to 4 h after 3rd dose, days 7, 14, 21, and 28Samples were analyzed by HPLC4/81/1
    UgandaeDetermine PK parameters for AS and AQ in children (Mwesigwa et al. [25])AS (50-mg tablets at 4 mg/kg twice a day for 3 days) + AQ (200-mg tablets at 10 mg/kg once a day on the first 2 days and 5 mg/kg on the third day), 200 mg amodiaquine hydrochloride (153 mg amodiaquine base)Children (ages, 5 to 13 yr)AS + AQ, loose formulationSanofi-Aventis, France20Just prior to 3rd dose and at 2, 4, 8, 24, and 120 h after 3rd doseA venous sample was drawn into potassium oxalate-sodium fluoride tubesSamples were stored at −80°C and analyzed by LC-MS/MS2/65/5
    Burkina FasocCompare bioavailability of fixed doses of AS and AQ vs AS and AQ separately (Stepniewska et al. [22])AS-AQ at a fixed dose (one dose of 25/67.5 mg/kg for children <12 mo of age or two doses for children ages 12 to 60 mo) or AS (50-mg tablet, a half tablet for children <12 mo of age and one tablet for children ages 12 to 60 mo) + AQ (153 mg, a half tablet for children <12 mo of age and one tablet for children ages 12 to 60 mo) daily for 3 days, 200 mg amodiaquine hydrochloride (153 mg amodiaquine base)Children (ages, 1 to 5 yr)AS + AQ at a fixed dose and as a loose formulationSanofi-Aventis, France61Before the 1st dose, 4 h after the 3rd dose, and then at days 7 and 14 and days 21 and 28A venous sample was collected in lithium heparin tubesSamples were stored at −20°C and analyzed by LC-MS/MS2/31/1
    GhanacCompare the effect of AS on AQ (comparison between AQ and loose formulations of AS and AQ) (Adjei et al. [20])AQ (10-mg/kg single dose) or AS (4-mg/kg single dose) + AQ (10-mg/kg single dose) daily for 3 days, 200 mg amodiaquine hydrochloride (153 mg amodiaquine base)Children (ages, 1 to 14 yr)AS + AQ, loose formulationPfizer, Dakar, Senegal101Before the dose on days 3 and 7A venous sample was collected into heparinized polypropylene tubesSamples were stored at −20°C and analyzed by HPLC1/210/10
    • ↵a All samples were venous plasma. AS, artesunate; AQ, amodiaquine; LLOQ, lower limit of quantification; DEAQ, desethylamodiaquine; LC-MS/MS, liquid chromatography-tandem mass spectrometry; HPLC, reverse-phase high-performance liquid chromatography.

    • ↵b Median number of amodiaquine/desethylamodiaquine samples per subject; values in parentheses are for the same women at 3 months postdelivery.

    • ↵c Population PK study.

    • ↵d The same women were sampled again at 3 months postdelivery during another malaria episode.

    • ↵e Noncompartmental pharmacokinetic analysis.

  • TABLE 3

    Parameter estimates of the population pharmacokinetic model for amodiaquine and desethylamodiaquinef

    Drug and parameterTypical valueaBSV or BOVa,b
    Value (% RSE)95% CIBSV (% RSE)BOV (% RSE)% shrinkage95% CI
    EtaEpsilon
    Amodiaquine
        Ka (1/h)0.589 (23)0.409, 0.90578.5 (12)41.762.0, 96.5
        MTT (h)0.236 (26)0.161, 0.33493.4 (16)61.860.6, 120
        NN2.00 (78)1.09, 6.31
        F1 Fixed30.9 (8.0)27.126.5, 36.0
        CLAQc (liters/h)2,960 (4.4)2,600, 3,11832.2 (13)44.324.2, 39.5
        VcAQc (liters)13,500 (19)7,423, 17,82453.1 (30)55.419.4, 79.5
        QAQc (liters/h)2,310 (9.2)1,877, 2,722
        VpAQc (liters)22,700 (10)17,956, 27,114
        Additive errord (ng/ml)LLOQ/5 + 0.445 (19)LLOQ/5 + 0.249, 0.60926.7
        Proportional error (%)19.9 (11)16.1, 24.6
    Desethylamodiaquine
        CLDEAQc (liters/h)32.6 (2.9)29.7, 33.420.0 (10)31.315.5, 23.5
        VcDEAQc (liters)258 (12)201, 31867.2 (21)59.336.0, 89.2
        Q1DEAQc (liters/h)154 (6.6)131, 171
        Vp1DEAQc (liters)2,460 (5.9)2,129, 2,677
        Q2DEAQc (liters/h)31.3 (6.2)26.8, 34.3
        Vp2DEAQc (liters)5,580 (4.3)4,968, 5,904
        Additive errord (ng/ml)LLOQ/5 Fixed16.5
        Proportional error (%)24.2 (4.0)22.2, 25.9
    Covariate effects
        PMA50 for AQe (time [mo] from conception)11.8 (4.6)10.50, 12.70
        Hill factor for AQe3.6 (4.0)3.23, 3.80
        PMA50 for DEAQe (time [mo] from conception)12.9 (5.7)11.60, 14.30
        Hill factor for DEAQe3.22 (4.7)2.85, 3.43
        Effect of first dose on F (%)−22.4 (19)−32.0, −15.6
    • ↵a The precision of the parameter estimates was assessed using a nonparametric bootstrap of the final model (n = 500). The relative standard errors were calculated as 100 × (standard deviation/mean), while the confidence intervals were obtained on the basis of the empirical percentiles of the bootstrap estimates.

    • ↵b Between-subject and between-occasion variability were assumed to be log-normally distributed and are reported as the approximate percent coefficient of variation.

    • ↵c All clearances and volumes of distribution refer to a patient weighing 50 kg, the median weight in the data set.

    • ↵d For the data contributed by each study, the additive error was fixed to 20% of the lower limit of quantification (LLOQ) in that study plus an estimated parameter. For desethylamodiaquine, this extra parameter was not significantly different from zero, so the additive error was fixed to the lower bound of LLOQ/5.

    • ↵e Estimated using prior functionality in NONMEM.

    • ↵f Abbreviations: AQ, amodiaquine; DEAQ, desethylamodiaquine; BSV, between-subject variability; BOV, between-occasion variability; RSE, relative standard error; Ka, absorption rate constant; MTT, mean transit time; NN, number of transit compartments; F, relative bioavailability; CL, clearance; Vc, central volume of distribution; Q, Q1, and Q2, intercompartmental clearances; Vp, Vp1, and Vp2, peripheral volumes of distribution; PMA50, time to reach 50% of clearance maturation; Hill factor, steepness of the clearance maturation curve.

  • TABLE 4

    Current dose regimen and optimized dose regimen based on simulations for amodiaquine

    Current manufacturer dose regimenProposed dose regimen
    Body wt (kg)No. of tablets/day, tablet strengthTotal amodiaquine dose (mg)Body wt (kg)No. of tablets/day, tablet strength (mg)Total amodiaquine dose (mg)
    4 to 81, 67.567.54 to 6a1, 67.567.5
    9 to 171, 1351357 to 10b1, 135135
    18 to 351, 27027011 to 161.5, 135c202.5
    ≥362, 27054017 to 282.5, 135c337.5
    29 to 492, 270540
    ≥503, 270810
    • ↵a A substantial number of simulated patients (78%) in this weight band were younger (<1 year) than those available in the data set.

    • ↵b A proportion of the simulated patients (38%) in this weight band were younger (<1 year) than those available in the data set.

    • ↵c In these weight bands, as an alternative to splitting tablets, one could suggest using tablets of different strengths. Either option is viable, according to the preference of the caregiver.

Additional Files

  • Figures
  • Tables
  • Supplemental material

    • Supplemental file 1 -

      Supplemental Figures S1 and S2

      PDF, 1.4M

PreviousNext
Back to top
Download PDF
Citation Tools
Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing
Ali Mohamed Ali, Melissa A. Penny, Thomas A. Smith, Lesley Workman, Philip Sasi, George O. Adjei, Francesca Aweeka, Jean-René Kiechel, Vincent Jullien, Marcus J. Rijken, Rose McGready, Julia Mwesigwa, Kim Kristensen, Kasia Stepniewska, Joel Tarning, Karen I. Barnes, Paolo Denti, for the WWARN Amodiaquine PK Study Group
Antimicrobial Agents and Chemotherapy Sep 2018, 62 (10) e02193-17; DOI: 10.1128/AAC.02193-17

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Population Pharmacokinetics of the Antimalarial Amodiaquine: a Pooled Analysis To Optimize Dosing
Ali Mohamed Ali, Melissa A. Penny, Thomas A. Smith, Lesley Workman, Philip Sasi, George O. Adjei, Francesca Aweeka, Jean-René Kiechel, Vincent Jullien, Marcus J. Rijken, Rose McGready, Julia Mwesigwa, Kim Kristensen, Kasia Stepniewska, Joel Tarning, Karen I. Barnes, Paolo Denti, for the WWARN Amodiaquine PK Study Group
Antimicrobial Agents and Chemotherapy Sep 2018, 62 (10) e02193-17; DOI: 10.1128/AAC.02193-17
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • INTRODUCTION
    • RESULTS
    • DISCUSSION
    • MATERIALS AND METHODS
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

NONMEM
dose optimization
malaria
pediatrics

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596